Ribavirin is the first synthetic, broad-spectrum antiviral nucleoside. Despite its more than 30 year history, the mechanism of action of this compound remains unclear and somewhat controversial. Recent data suggest the possibility that the activity of ribavirin against RNA viruses is a reflection of incorporation of ribavirin into the viral genome. Because ribavirin incorporation is not specific, this event leads to lethal mutagenesis of the virus population. The data supporting this new proposal for the mechanism of action of ribavirin are reviewed herein. In addition, we discuss briefly the challenges that remain for development of lethal mutagenesis as an effective antiviral strategy. © 2002 Elsevier Science (USA) 
MECHANISMS OF ACTION OF RIBAVIRIN
Ribavirin (1-␤-D-ribofuranosyl-1,2,4-triazole-3-carboxamide, also known as virazole) is the first synthetic, broad-spectrum antiviral nucleoside ( Fig. 1) (Sidwell et al., 1972) . It is currently used clinically in combination with interferon-␣ for treatment of hepatitis C virus (HCV) infection (Cummings et al., 2001; Di Bisceglie et al., 2001) and as a monotherapy for treatment of Lassa fever virus (Andrei and De Clercq, 1993; Huggins, 1989 ) and respiratory syncytial virus (Krilov, 2001) infections. Ribavirin is administered as the nucleoside. Once in the cell, ribavirin is rapidly converted to ribavirin monophosphate (RMP) by adenosine kinase. Sequential phosphorylation leads to the formation and accumulation of ribavirin triphosphate (RTP).
While ribavirin exhibits antiviral activity against a wide range of DNA and RNA viruses in the laboratory, the mechanism of action of this compound is still debated. Ribavirin monophosphate has been shown to be an inhibitor of inosine monophosphate dehydrogenase (IMPDH), a cellular enzyme required for the de novo synthesis of guanosine triphosphate (GTP) (Muller et al., 1977; Streeter et al., 1973) . Treatment of cells with ribavirin results in a twofold reduction in intracellular GTP (Muller et al., 1977) . Because GTP is required for translation, transcription, and/or replication of all viruses, subtle reductions in the cellular GTP pool could account for the broad-spectrum antiviral activity of ribavirin.
Although current dogma maintains IMPDH as the tar-get for the antiviral activity of ribavirin, not all IMPDH inhibitors possess antiviral activity (Crotty et al., 2000; Lanford et al., 2001) . Over the past 30 years, several alternative hypotheses for the antiviral activity of ribavirin have been put forward, including inhibition of capping of viral RNA transcripts (Scheidel and Stollar, 1991) , direct inhibition of the viral RNA polymerase (Eriksson et al., 1977) , and modulation of the host immune response (Fang et al., 2000; Zuckerman et al., 2001) . In addition, it has been suggested that the antiviral activity of ribavirin may reflect direct incorporation into RNA. Indeed, RTP accumulates to high levels in some tissues (Zimmerman and Deeprose, 1978) . However, attempts to demonstrate incorporation into viral RNA by using radiolabeled ribavirin have been unsuccessful, suggesting very low or no incorporation into RNA.
Recently, a novel primer-extension assay which utilizes end-labeled primers was developed to monitor the activity of poliovirus RNA-dependent RNA polymerase (RdRP) . When this assay was employed to evaluate utilization of RTP by poliovirus polymerase, direct incorporation of ribavirin into RNA was observed (Crotty et al., 2000) . In general, the maximal rate of incorporation of ribavirin was equivalent to that of an incorrect nucleotide, 0.014-0.019/s. This value is 3000-to 6000-fold slower than that measured for incorporation of a correct nucleotide in this context. Therefore, less than three molecules of ribavirin will be incorporated per genome per replication cycle, and the actual value will be dependent upon the intracellular concentration of RTP. The apparent binding constant for RTP is in the 400-to 500-M regime. In addition, it was noted that ribavirin was templated equivalently by both 1 To whom correspondence and reprint requests should be addressed. Fax: 814-865-7927. E-mail: cec9@psu.edu. Virology 298, 175-180 (2002 Virology 298, 175-180 ( ) doi:10.1006 Virology 298, 175-180 ( /viro.2002 Virology 298, 175-180 ( .1487 0042-6822/02 $35.00 cytidine and uridine. This promiscuous basepairing capacity of ribavirin is likely due to the two different configurations assumed by the carboxamide moiety of the pseudobase of ribavirin ( Fig. 1) . Additional experiments with RNA containing ribavirin confirmed that ribavirin templates incorporation of cytidine and uridine with equal efficiency. The ability of ribavirin to basepair with both cytidine and uridine suggests that ribavirin should increase the frequency of transition mutations in the viral genome.
It is known that poliovirus replication is inhibited by the presence of 2 mM guanidine and that resistance to guanidine is conferred by a single transition mutation in the viral 2C-coding region (Baltera and Tershak, 1989) . Replication in the presence of guanidine requires a C to U transition that occurs naturally in the poliovirus population at a frequency of 10 Ϫ5 . If ribavirin is an RNA virus mutagen, then by growing virus in the presence of this compound an increase in the occurrence of guanidineresistant virus in the population would be expected. Indeed, increasing the ribavirin concentration in which virus was grown resulted in a dose-dependent increase of guanidine-resistant variants in the population. These data provide further support for the ability of ribavirin to act as a mutagen (Crotty et al., 2000) . This new mechanism of action for ribavirin is illustrated schematically in Fig. 2 . It is worth noting that lethal mutagenesis may also be the operative mechanism for the anti-HCV activity of ribavirin as the HCV RdRP incorporates ribavirin opposite cytidine and uridine with equal efficiency (Maag et al., 2001) .
FIG. 1. Ribavirin exhibits promiscuous basepairing capacity. Rotation of the carboxamide moiety of the pseudobase permits hydrogen bonding to both cytosine and uracil. "R" denotes ribose.
FIG. 2.
Ribavirin incorporation increases the mutation rate of RNA viruses. A typical poliovirus replication cycle results in approximately 1.5 mutations per progeny genome (left). Infection in the presence of 400 M ribavirin (right) results in approximately 6.9 mutations per genome and a reduction in viral fitness to 5% of the wild-type population (Crotty et al., 2001) . Ribavirin monophosphate is an IMPDH inhibitor, resulting in a twofold reduction of cellular GTP, while the triphosphate (RTP) can be incorporated directly into viral RNA.
QUASISPECIES AND ERROR CATASTROPHE
Given that ribavirin incorporation into the poliovirus genome is mutagenic, the question arises: how susceptible is poliovirus to the accumulation of additional mutations? Poliovirus polymerase, similar to other RdRPs, lacks a proofreading activity, causing the virus to exist as a quasispecies-that is, an extremely heterogeneous population in which each member differs from another by a finite number of changes in the viral genome (Domingo et al., 1985) . Although the use of the term quasispecies by virologists as it relates to RNA virus evolution has been challenged (Holmes and Moya, 2002) , the concept as applied by virologists has led to significant contributions in understanding the RNA virus lifecycle and pathogenesis (Domingo, 2002) . The quasispecies nature of RNA viruses produces a spectrum of phenotypic variants which can rapidly evolve in response to changing environmental conditions such as the host immune response or clinical intervention.
However, there must be some level of "diversity" in which the virus is forced into error catastrophe-that is, the point at which the number of mutations per genome is too large for viability. Error catastrophe theory predicts that once the error threshold is reached, even a slight increase in mutation frequency should cause a dramatic reduction in virus viability. RNA viruses should be particularly sensitive to mutation because their genomes are so informationally dense, encoding gene products as well as RNA structural signals for translation and replication. If increased genetic diversity is an important contributor to the fitness of an RNA virus population, then it is likely that viruses have evolved to exist on the threshold of error catastrophe-that is, the point of maximal adaptability.
Crotty and colleagues have exploited ribavirin mutagenesis to evaluate the effect of mutations on the fitness of poliovirus (Crotty et al., 2001) . The normal poliovirus population has approximately 1.5 mutations per genome based upon sequence analysis of several genome equivalents of capsid-coding sequence. By growing poliovirus in a range of ribavirin concentrations, the mutation frequency could be increased to 10-fold greater than that of the normal population. The specific infectivity of RNA containing the random mutations was measured and plotted vs the average number of mutations per genome (Fig. 3) . A dramatic decrease in infectivity was observed when the mutation frequency exceeded approximately two mutations per genome. This graph suggests that poliovirus has evolved to exist on the threshold of error catastrophe and proves that ribavirin can have a direct effect on viral RNA.
The recent development of a tamarin hepatocyte tissue culture system for GB virus B (GBV-B) , a close relative of HCV, has provided further evidence for the incor-poration of ribavirin into viral RNA (Lanford et al., 2001) . Pretreatment of cells with 100 M ribavirin prior to infection resulted in an almost 10 4 -fold decrease in cellassociated viral RNA after infection. In agreement with data obtained for poliovirus, the specific infectivity of GBV-B RNA was decreased substantially by growth of virus in the presence of ribavirin.
Together, these new data support the idea that ribavirin is a lethal mutagen of RNA virus genomes. However, these studies failed to demonstrate extinction of the virus population by using ribavirin. The concept of lethal mutagenesis is not a new one. Holland and co-workers recognized first that small (less than threefold) increases in mutation frequency were sufficient to cause a significant reduction in virus viability by using both poliovirus and vesicular stomatitis virus as model systems (Holland et al., 1990) . Extinction of virus populations in the presence of mutagens has been documented in a number of systems. Loeb and colleagues found that a slight increase in mutation frequency of human immunodeficiency virus resulted in a significant reduction in virus viability. Moreover, serial passage of the virus in the presence of a mutagen that increased the mutation frequency only threefold was sufficient for viral extinction (Loeb and Mullins, 2000) . Domingo and colleagues demonstrated efficient extinction of foot-and-mouth disease virus in the combined presence of a mutagen (5-fluorouracil) and viral inhibitor (guanidine) without observing an increase in mutations conferring resistance to the inhibitor (Pariente et al., 2001) . RNA produced by in vitro transcription of a cDNA clone shows a subtle increase in specific infectivity relative to RNA isolated from virions. The LI 50 (50% loss of specific infectivity) is defined as the mutation frequency at which 50% of viral genomes are lethally mutated. Wild-type (wt) poliovirus genomes contain an average of 1.5 mutations. Poliovirus genomes isolated from cells treated with 100, 400, or 1000 M ribavirin contain 1.9, 6.9, or 15.5 mutations, respectively. Reproduced with permission from Crotty et al., Copyright 2001 , National Academy of Sciences, U.S.A.
The utilization of ribavirin as a substrate by the viral RdRP can explain the effectiveness of ribavirin against a diverse range of RNA viruses as the polymerase represents a common enzyme for these viruses. However, the proposed mechanisms of action for ribavirin are not mutually exclusive. Because ribavirin can compete with GTP for basepairing with UTP, a decrease in cellular GTP pools would be expected to favor incorporation of RTP as a GTP analog. In fact, reduction in the GTP pool may be necessary for efficient utilization of ribavirin. Additionally, incorporation of a base analog by the RdRP can have deleterious effects other than direct mutagenesis. For example, direct incorporation of ribavirin into RNA may impair codon-anticodon recognition during translation or disrupt Hoogsteen basepairing necessary for RNA structure. Another possibility is that ribavirin may utilize different modes of action against different viruses. For example, the primary target of ribavirin against Sindbis virus is the guanylyl transferase activity as ribavirinresistant variants contain changes in guanylyl-transferase-coding sequence (Scheidel and Stollar, 1991) .
LETHAL MUTAGENESIS AS AN ANTIVIRAL STRATEGY
If the data obtained for poliovirus and GBV-B hold true for other RNA viruses, then an analog causing a small increase in mutation frequency may be sufficient to drive other viruses into error catastrophe. How do we translate these findings for ribavirin into novel and more effective antiviral therapies? Examination of the nucleoside base suggests two categories of mutagenic nucleosides: those with ambiguous basepairing capacity (i.e., hydrogen-bonding); and those with ambiguous interaction capacity that do not rely on hydrogen bonding. Both types of molecules are referred to as universal bases (Loakes, 2001) .
The latter has no basepairing properties but forms stable duplexes in DNA or RNA irrespective of the particular base against which it is paired. Stability is achieved through base-stacking interactions due to the hydrophobic character of the aromatic base residue. An example of this type of pseudobase is 3-nitropyrrole (3-NP) (Fig. 4A ). The utility of 3-NP as a nonspecific analog for DNA probes and primers has been well documented in the laboratory (Loakes, 2001) . However, the effectiveness of non-hydrogen-bonding, universal ribonucleosides as antiviral agents remains to be tested. It is possible that hydrogen-bonding interactions are essential for recognition by the RdRP for incorporation of these analogs into the genome at a high enough rate to induce lethal mutagenesis.
A good example of an ambiguous, hydrogen-bonding analog is nucleoside P (Fig. 4B ). This pseudobase pairs with both adenosine and guanosine and has been shown to increase mutation frequency in an in vitro retroviral replication model (Lin and Brown, 1989; Moriyama et al., 2001) . Furthermore, as a pyrimidine analog, this compound may potentially be required at a lower level than purine analogs because the competing intracellular pyrimidine pool is much lower than that of purines (Traut, 1994) .
In light of the findings for ribavirin, it may be worthwhile to evaluate other known antiviral compounds for mutagenic potential. A number of established antivirals are nucleoside analogs and are known to be phosphorylated to the triphosphate by cellular enzymes, but their antiviral activity has been attributed to inhibition of nucleotide biosynthesis (De Clercq, 1993) . For instance, pyrazofurin is a nucleoside analog with a structure similar to ribavirin (Fig. 4C ). It has demonstrated antiviral activity attributed to the monophosphate's ability to inhibit cellular ovotidine monophosphate (OMP) decarboxylase, an enzyme required for pyrimidine biosynthesis (Cadman et al., 1978; Dix et al., 1979) . All OMP decarboxylase inhibitors are not antivirals, a situation reminiscent of that for ribavirin (Rada and Dragun, 1977) . It may be possible that viral polymerases are able to effectively utilize the triphosphate of pyrazofurin for incorporation into RNA. The structure of pyrazofurin indicates that it too may have ambiguous basepairing interactions. It is known that the triphosphate accumulates in cells treated with the nucleoside (Zimmerman and Deeprose, 1978) .
Development of mutagenic nucleosides for clinical use requires not just utilization of the compound by the Pyrazofurin is a known antiviral with a structure similar to ribavirin-RdRP but also consideration of cellular toxicity and clinical side effects. The cellular enzyme ribonucleotide reductase is required for conversion of ribonucleotides to deoxyribonucleotides. Nucleoside analogs containing modified sugar residues may be able to escape recognition by this enzyme and hence be unable to participate in DNA replication, eliminating the possibility of longterm and heritable changes to the host genome. Toxicity is often also attributed to changes in cellular nucleoside triphosphate (NTP) pools by inhibition of nucleotide biosynthesis. Sugar modification may also prevent these analogs from affecting such metabolic pathways. However, intracellular phosphorylation to the triphosphate by host kinases is required for incorporation. This obstacle can be overcome synthetically by chemical phosphorylation and protection to permit delivery into cells and activation therein (Wagner et al., 2000) . Designing a molecule that can be incorporated into viral genomes without affecting cellular NTP pools and host replication will prove challenging because our current understanding of substrate recognition by enzymes involved in nucleotide metabolism is very limited.
In summary, recent studies of the antiviral mechanisms of ribavirin offer support for a new class of antivirals-namely, lethal mutagens. Identification of mutagenic nucleosides that can escape recognition by cellular enzymes and be utilized by the viral polymerase will be required to pursue this strategy for antiviral therapy.
